The Goldman Sachs Group Issues Pessimistic Forecast for UroGen Pharma (NASDAQ:URGN) Stock Price
UroGen Pharma (NASDAQ:URGN – Free Report) had its price objective cut by The Goldman Sachs Group from $16.00 to $3.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other research analysts have also recently commented on URGN. LADENBURG THALM/SH SH assumed coverage on […]
UroGen Pharma (NASDAQ:URGN – Free Report) had its price objective cut by The Goldman Sachs Group from $16.00 to $3.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other research analysts have also recently commented on URGN. LADENBURG THALM/SH SH assumed coverage on […]
